Sensitivity of H5N1 influenza viruses to oseltamivir: An update

Future Virology

Volumn 3, Issue 2, 2008, Pages 157-165

  Rameix Welti, Marie Anne ^a   van der Werf, Sylvie ^a   Naffakh, Nadia ^a  

^a CNRS   (France)

Author keywords

Antiviral resistance; Antiviral therapy; H5N1; Influenza; Neuraminidase inhibitors; Oseltamivir; Pandemic preparedness

Indexed keywords

AMANTADINE; ASPARAGINE; HISTIDINE; INFLUENZA VACCINE; INTERFERON; OSELTAMIVIR; RIBAVIRIN; RIMANTADINE; SERINE; SIALIDASE; SIALIDASE INHIBITOR; TYROSINE; ZANAMIVIR;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CAMBODIA; CELL CULTURE; CHINA; DISEASE MODEL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; FERRET; HEALTH CARE PLANNING; HONG KONG; HUMAN; IN VITRO STUDY; INDONESIA; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS A H5N1; MEDICAL DECISION MAKING; MORTALITY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; STRAIN DIFFERENCE; THAILAND; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; TURKEY (REPUBLIC); VIET NAM; VIRUS SHEDDING; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALIA; INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE;

EID: 40749095573     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460794.3.2.157     Document Type: Review

References (65)

1. Claas EC, Osterhaus AD, van Beek R et al.: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351, 472-477 (1998).
2. Subbarao K, Klimov A, Katz J et al.: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279, 393-396 (1998).
3. WHO: Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis. 11, 1515-1521 (2005).
4. Ong AK, Hayden FG, John F: Enders lecture 2006: antivirals for influenza. J. Infect. Dis. 196, 181-190 (2007).
5. Cheung CL, Rayner JM, Smith GJ et al.: Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 193, 1626-1629 (2006).
6. Jefferson T, Dernicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A: Antivirals for influenza in healthy adults: systematic review. Lancet 367, 303-313 (2006).
7. Russell RJ, Haire LF, Stevens DJ et al.: The structure of H5N1 avian influenza neuraminiclase suggests new opportunities for drug design. Nature 443(7107), 45-49 (2006).
8. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG: The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 48, 101-115 (2000).
9. Yen HL, Herlocher LM, Hoffmann E et al.: Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 49, 4075-4084 (2005).
10. Wetherall NT, Trivedi T, Zeller J et al.: Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 41, 742-750 (2003).
11. Hurt AC, Selleck P. Komadina N, Shaw R, Brown L, Barr IG: Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 73, 228-231 (2007).
12. McKimm-Breschkin JL, Selleck P, Usman T, Johnson M: Indonesian H5N1 isolates demonstrate decreased sensivtivity to oseltamivir. Presented at: Options for the Control of Influenza VI Conference. Toronto, Canada, 17-23 June 2007 (Abstract 69).
13. Rameix-Welti MA, Agou F, Buchy P et al.: Natural variation can significantly alter sensitivity to oseltamivir of Influenza A(H5N1) viruses. Antimicrob. Agents Chemother. 50(11), 3809-3815(2006).
14. Ives JA, Carr JA, Mendel DB et al.: The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res. 55, 307-317 (2002).
15. Kati WM, Montgomery D, Carrick R et al.: In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother. 46, 1014-1021 (2002).
16. Wang MZ, Tai CY, Mendel DB: Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 46, 3809-3816 (2002).
17. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk HD: Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J. Virol. 77, 8418-18425 (2003).
18. Zambon M, Hayden FG: Position statement: global neuraminidase, inhibitor susceptibility network. Antiviral Res. 49, 147-156 (2001).
19. Wagner R, Matrosovich M, Klenk HD: Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12, 159-166 (2002).
20. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA: Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312, 404-410 (2006).
21. Yen HL, Monto AS, Webster RG, Govorkova EA: Vindence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J. Infect. Dis. 192, 665-672 (2005).
22. Govorkova. EA, Leneva IA, Goloubeva OG, Bush K, Webster RG: Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 45, 2723-2732 (2001).
23. Govorkova EA, Rehg JE, Krauss S et al.: Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol. 79, 2191-2198 (2005).
24. Maines TR, Lu XH, Erb SM et al.: Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 79, 11788-11800 (2005).
25. Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM: Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 76, 4420-4429 (2002).
26. Govorkova EA, Ilyushina NA. Boltz DA, Douglas A, Yilmaz N, Webster RG: Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 51, 1414-1424 (2007).
27. Peiris JS, Yu WC, Leung CW et al.: Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 363, 617-619 (2004).
28. Apisarnthanarak A, Kitphati R, Thongphubeth K et al.: Atypical avian influenza (H5N1). Emerg. Infect. Dis. 10, 1321-1324 (2004).
29. Beigel JH, Farrar J, Han AM et al.: Avian influenza A (H5N1) infection in humans. N. Ergl. J. Med. 353, 1374-1385 (2005).
30. Chokephaibulkit K, Uiprasertkul M, Puthavathana P et al.: A child with avian influenza A (H5N1) infection. Pediatr. Infect. Dis. J. 24, 162-166 (2005).
31. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W et al.: Human disease from influenza A (H5N1), Thailand, 2004 Emerg. Infect. Dis. 11, 201-209 (2005).
32. Chutinimitkul S, Bhattarakosol P, Srisuratanon S et al.: H5N1 influenza A virus and infected human plasma. Emerg. Infect. Dis. 12, 1041-1043 (2006).
33. Ungchusak K, Auewarakul P, Dowell SF et al.: Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med. 352, 333-340 (2005).
34. de Jong MD, Bach VC, Phan TQ et al.: Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med. 352, 686-691 (2005).
35. de Jong MD, Simmons CP, Thanh TT et al.: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12, 1203-1207 (2006).
36. de Jong MD, Tran TT, Truong HK et al.: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 353, 2667-2672 (2005).
37. Le QM, Kiso M, Someya K et al.: Avian flu: isolation of drug-resistant H5N1 virus. Nature 437, 1108 (2005).
38. Tran TH, Nguyen TL, Nguyen TD et al.: Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 350, 1179-1188 (2004).
39. Buchy P, Mardy S, Vong S et al.: Influenza A/H5N1 virus Infection in humans in Cambodia. J. Clin. Virol. 39, 164-168 (2007).
40. Kandun IN, Wibisono H, Sedyaningsih ER et al.: Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med. 355, 2186-2194 (2006).
41. Oner AF, Bay A, Arsian S et al.: Avian influenza A (H5N1) infection in eastern Turkey in 2006. N. Engl. J. Med. 355, 2179-2185 (2006).
42. Gu J, Xie Z, Gao Z et al.: H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet 370, 1137-1145 (2007).
43. Shu Y, Yu H, Li D: Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China. N. Engl. J. Med. 354, 1421-1422 (2006).
44. Sedyaningsih ER, Isfandari S, Setiawaty V et al.: Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005-June 2006. J. Infect. Dis. 196, 522-527 (2007).
45. Aoki FY, Macleod MD, Paggiaro P et al.: Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother. 51, 123-129 (2003).
46. Treanor JJ, Hayden FG, Vrooman PS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283, 1016-1024 (2000).
47. Whitley RJ, Hayden FG, Reisinger KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis, J. 20, 127-133 (2001).
48. Uiprasertkul M, Puthavathana P, Sangsiriwut K et al.: Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis. 11, 1036-1041 (2005).
49. Ng WF, To KF: Pathology of human H5N1 infection: new findings. Lancet 370, 1106-1108 (2007).
50. Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang KY, Cundy KC: Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Melab. Dupos. 28, 737-741 (2000).
51. Ward P, Small I, Smith J, Suter P, Dutkowski R: Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J. Antimicrob. Chemother. 55(Suppl. 1), I5-I21 (2005).
52. Nicholson KG, Aoki FY, Osterhaus AD et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355, 1845-1850 (2000).
53. Kiso M, Mitamura K, Sakai-Tagawa Y et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364, 759-765 (2004).
54. Aoki FY, Boivin G, Roberts N: Influenza virus susceptibility and resistance to oseltamivir. Antivir. Ther. 12, 603-616 (2007).
55. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG: Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis. 183, 523-531 (2001).
56. Saad MD, Boynton BR, Earhart KC et al.: Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. Presented at: Options for the Control of Influenza VI Conference. Toronto, Canada, 17-23 June 2007.
57. Gubareva LV, Webster RG, Hayden FG: Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45, 3403-3408 (2001).
58. Fritz RS, Hayden FG, Calfee DP et al.: Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis. 180, 586-593 (1999).
59. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA: Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 81, 12418-12426 (2007).
60. Herlocher ML, Truscon R, Elias S et al.: Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dus. 190, 1627-1630 (2004).
61. Mishin VP, Hayden FG, Gubareva LV: Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 49, 4515-4520 (2005).
62. Macdonald SJ, Cameron R, Demaine DA et al.: Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem. 48, 2964-2971 (2005).
63. Malakhov MP, Aschenbrenner LM, Smee DF et al.: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 50, 1470-1479 (2006).
64. Takahashi K, Furuta Y, Fukuda Y et al.: In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother. 14, 235-241 (2003).
65. De Clercq E: Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5, 1015-1025 (2006).